1-9 of 9
Elizabeth Wise
Close
Sort by
Journal Articles

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS

Leylah Drusbosky, PhD, Elizabeth Wise, BS, Shireen Vali, PhD, Taher Abbasi, Ansu Kumar, Neeraj Kumar Singh, Kabya Basu, Chandan Kumar, Amjad Husain, Fei Zou, PhD, Caitlin Tucker, BS, Randy A Brown, MD, Maxim Norkin, MD PhD, John Hiemenz, MD, John R. Wingard, MD, Jack W Hsu, MD, Christopher R. Cogle, MD
Journal: Blood
Blood (2016) 128 (22): 594.
https://doi.org/10.1182/blood.V128.22.594.594
Published: 2016
Journal Articles

Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells

Nancy Y. Villa, Clive H. Wasserfall, Amy M. Meacham, Elizabeth Wise, Winnie Chan, John R. Wingard, Grant McFadden, Christopher R. Cogle
Journal: Blood
Blood (2015) 125 (24): 3778–3788.
https://doi.org/10.1182/blood-2014-07-587329
Published: 2015
Includes: Supplemental data
Journal Articles

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

Raphael C Bosse, BS, Briana Wasserstrom, Elizabeth Wise, BS, Amy Meacham, MS, Christopher R. Cogle, MD
Journal: Blood
Blood (2014) 124 (21): 2315.
https://doi.org/10.1182/blood.V124.21.2315.2315
Published: 2014
Journal Articles

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Daniel Turner, BS, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Raphael C Bosse, BS, Dai Chaplin, PhD, Jack W. Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, Maxim Norkin, MD, PhD, John R Wingard, MD, Christopher R Cogle, MD
Journal: Blood
Blood (2013) 122 (21): 1463.
https://doi.org/10.1182/blood.V122.21.1463.1463
Published: 2013
Journal Articles

Bone Marrow Endothelial Cells Protect Acute Myeloid Leukemia From Chemotherapy By Direct Contact: The BCAM/Laminin/VLA5 Axis As a Potential Therapeutic Target

Leylah Drusbosky, BS, Amy Meacham, MS, Elizabeth Wise, BS, Edward W Scott, PhD, Christopher R Cogle, MD
Journal: Blood
Blood (2013) 122 (21): 2546.
https://doi.org/10.1182/blood.V122.21.2546.2546
Published: 2013
Journal Articles

Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells by Depolymerizing the Microtubule Cytoskeleton.

Raphael C Bosse, BS, Sunil Rohatgi, BS, Amy Meacham, MS, Elizabeth Wise, BS, Edward W Scott, PhD, Christopher R Cogle, MD
Journal: Blood
Blood (2012) 120 (21): 2183.
https://doi.org/10.1182/blood.V120.21.2183.2183
Published: 2012
Journal Articles

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Christopher R Cogle, MD, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Maxim Norkin, MD, PhD, David Chaplin, PhD, Jai Balkissoon, MD, Jack W Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, John R Wingard, MD
Journal: Blood
Blood (2012) 120 (21): 4335.
https://doi.org/10.1182/blood.V120.21.4335.4335
Published: 2012
Journal Articles

AML Depends on VEGFR1 and Not VEGFR2 for Proliferation and Protection From Chemotherapy,

Swarna Bais, Ph.D., Elizabeth Wise, B.S., Eric M. Harris, DO, Amy Meacham, MS, Christopher R Cogle, M.D.
Journal: Blood
Blood (2011) 118 (21): 3598.
https://doi.org/10.1182/blood.V118.21.3598.3598
Published: 2011
Journal Articles

Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib.

Eric Gars, Christie S McGee, Raphael C Bosse, Elizabeth Wise, Amy Meacham, MS, Christopher R. Cogle, MD
Journal: Blood
Blood (2010) 116 (21): 1057.
https://doi.org/10.1182/blood.V116.21.1057.1057
Published: 2010